Pharmacological treatment options for mast cell activation disease

Gerhard J. Molderings, Britta Haenisch, Stefan Brettner, Jürgen Homann, Markus Menzen, Franz Ludwig Dumoulin, Jens Panse, Joseph Butterfield, Lawrence B. Afrin

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Mast cell activation disease (MCAD) is a term referring to a heterogeneous group of disorders characterized by aberrant release of variable subsets of mast cell (MC) mediators together with accumulation of either morphologically altered and immunohistochemically identifiable mutated MCs due to MC proliferation (systemic mastocytosis [SM] and MC leukemia [MCL]) or morphologically ordinary MCs due to decreased apoptosis (MC activation syndrome [MCAS] and well-differentiated SM). Clinical signs and symptoms in MCAD vary depending on disease subtype and result from excessive mediator release by MCs and, in aggressive forms, from organ failure related to MC infiltration. In most cases, treatment of MCAD is directed primarily at controlling the symptoms associated with MC mediator release. In advanced forms, such as aggressive SM and MCL, agents targeting MC proliferation such as kinase inhibitors may be provided. Targeted therapies aimed at blocking mutant protein variants and/or downstream signaling pathways are currently being developed. Other targets, such as specific surface antigens expressed on neoplastic MCs, might be considered for the development of future therapies. Since clinicians are often underprepared to evaluate, diagnose, and effectively treat this clinically heterogeneous disease, we seek to familiarize clinicians with MCAD and review current and future treatment approaches.

Original languageEnglish (US)
Pages (from-to)671-694
Number of pages24
JournalNaunyn-Schmiedeberg's Archives of Pharmacology
Volume389
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Mastocytosis
Mast Cells
Systemic Mastocytosis
Pharmacology
Mast-Cell Leukemia
Cell Proliferation
Mutant Proteins
Surface Antigens
Signs and Symptoms
Leukemia
Phosphotransferases
Apoptosis
Therapeutics

Keywords

  • Mast cell
  • Mast cell activation disease
  • Systemic mast cell activation syndrome
  • Systemic mastocytosis
  • Therapy

Cite this

Molderings, G. J., Haenisch, B., Brettner, S., Homann, J., Menzen, M., Dumoulin, F. L., ... Afrin, L. B. (2016). Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg's Archives of Pharmacology, 389(7), 671-694. https://doi.org/10.1007/s00210-016-1247-1

Pharmacological treatment options for mast cell activation disease. / Molderings, Gerhard J.; Haenisch, Britta; Brettner, Stefan; Homann, Jürgen; Menzen, Markus; Dumoulin, Franz Ludwig; Panse, Jens; Butterfield, Joseph; Afrin, Lawrence B.

In: Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 389, No. 7, 01.07.2016, p. 671-694.

Research output: Contribution to journalReview article

Molderings, GJ, Haenisch, B, Brettner, S, Homann, J, Menzen, M, Dumoulin, FL, Panse, J, Butterfield, J & Afrin, LB 2016, 'Pharmacological treatment options for mast cell activation disease', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 389, no. 7, pp. 671-694. https://doi.org/10.1007/s00210-016-1247-1
Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL et al. Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg's Archives of Pharmacology. 2016 Jul 1;389(7):671-694. https://doi.org/10.1007/s00210-016-1247-1
Molderings, Gerhard J. ; Haenisch, Britta ; Brettner, Stefan ; Homann, Jürgen ; Menzen, Markus ; Dumoulin, Franz Ludwig ; Panse, Jens ; Butterfield, Joseph ; Afrin, Lawrence B. / Pharmacological treatment options for mast cell activation disease. In: Naunyn-Schmiedeberg's Archives of Pharmacology. 2016 ; Vol. 389, No. 7. pp. 671-694.
@article{49385fec089d4091838c8fc5ed142c29,
title = "Pharmacological treatment options for mast cell activation disease",
abstract = "Mast cell activation disease (MCAD) is a term referring to a heterogeneous group of disorders characterized by aberrant release of variable subsets of mast cell (MC) mediators together with accumulation of either morphologically altered and immunohistochemically identifiable mutated MCs due to MC proliferation (systemic mastocytosis [SM] and MC leukemia [MCL]) or morphologically ordinary MCs due to decreased apoptosis (MC activation syndrome [MCAS] and well-differentiated SM). Clinical signs and symptoms in MCAD vary depending on disease subtype and result from excessive mediator release by MCs and, in aggressive forms, from organ failure related to MC infiltration. In most cases, treatment of MCAD is directed primarily at controlling the symptoms associated with MC mediator release. In advanced forms, such as aggressive SM and MCL, agents targeting MC proliferation such as kinase inhibitors may be provided. Targeted therapies aimed at blocking mutant protein variants and/or downstream signaling pathways are currently being developed. Other targets, such as specific surface antigens expressed on neoplastic MCs, might be considered for the development of future therapies. Since clinicians are often underprepared to evaluate, diagnose, and effectively treat this clinically heterogeneous disease, we seek to familiarize clinicians with MCAD and review current and future treatment approaches.",
keywords = "Mast cell, Mast cell activation disease, Systemic mast cell activation syndrome, Systemic mastocytosis, Therapy",
author = "Molderings, {Gerhard J.} and Britta Haenisch and Stefan Brettner and J{\"u}rgen Homann and Markus Menzen and Dumoulin, {Franz Ludwig} and Jens Panse and Joseph Butterfield and Afrin, {Lawrence B.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1007/s00210-016-1247-1",
language = "English (US)",
volume = "389",
pages = "671--694",
journal = "Naunyn-Schmiedeberg's Archives of Pharmacology",
issn = "0028-1298",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Pharmacological treatment options for mast cell activation disease

AU - Molderings, Gerhard J.

AU - Haenisch, Britta

AU - Brettner, Stefan

AU - Homann, Jürgen

AU - Menzen, Markus

AU - Dumoulin, Franz Ludwig

AU - Panse, Jens

AU - Butterfield, Joseph

AU - Afrin, Lawrence B.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Mast cell activation disease (MCAD) is a term referring to a heterogeneous group of disorders characterized by aberrant release of variable subsets of mast cell (MC) mediators together with accumulation of either morphologically altered and immunohistochemically identifiable mutated MCs due to MC proliferation (systemic mastocytosis [SM] and MC leukemia [MCL]) or morphologically ordinary MCs due to decreased apoptosis (MC activation syndrome [MCAS] and well-differentiated SM). Clinical signs and symptoms in MCAD vary depending on disease subtype and result from excessive mediator release by MCs and, in aggressive forms, from organ failure related to MC infiltration. In most cases, treatment of MCAD is directed primarily at controlling the symptoms associated with MC mediator release. In advanced forms, such as aggressive SM and MCL, agents targeting MC proliferation such as kinase inhibitors may be provided. Targeted therapies aimed at blocking mutant protein variants and/or downstream signaling pathways are currently being developed. Other targets, such as specific surface antigens expressed on neoplastic MCs, might be considered for the development of future therapies. Since clinicians are often underprepared to evaluate, diagnose, and effectively treat this clinically heterogeneous disease, we seek to familiarize clinicians with MCAD and review current and future treatment approaches.

AB - Mast cell activation disease (MCAD) is a term referring to a heterogeneous group of disorders characterized by aberrant release of variable subsets of mast cell (MC) mediators together with accumulation of either morphologically altered and immunohistochemically identifiable mutated MCs due to MC proliferation (systemic mastocytosis [SM] and MC leukemia [MCL]) or morphologically ordinary MCs due to decreased apoptosis (MC activation syndrome [MCAS] and well-differentiated SM). Clinical signs and symptoms in MCAD vary depending on disease subtype and result from excessive mediator release by MCs and, in aggressive forms, from organ failure related to MC infiltration. In most cases, treatment of MCAD is directed primarily at controlling the symptoms associated with MC mediator release. In advanced forms, such as aggressive SM and MCL, agents targeting MC proliferation such as kinase inhibitors may be provided. Targeted therapies aimed at blocking mutant protein variants and/or downstream signaling pathways are currently being developed. Other targets, such as specific surface antigens expressed on neoplastic MCs, might be considered for the development of future therapies. Since clinicians are often underprepared to evaluate, diagnose, and effectively treat this clinically heterogeneous disease, we seek to familiarize clinicians with MCAD and review current and future treatment approaches.

KW - Mast cell

KW - Mast cell activation disease

KW - Systemic mast cell activation syndrome

KW - Systemic mastocytosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84964575916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964575916&partnerID=8YFLogxK

U2 - 10.1007/s00210-016-1247-1

DO - 10.1007/s00210-016-1247-1

M3 - Review article

VL - 389

SP - 671

EP - 694

JO - Naunyn-Schmiedeberg's Archives of Pharmacology

JF - Naunyn-Schmiedeberg's Archives of Pharmacology

SN - 0028-1298

IS - 7

ER -